TY - JOUR AU - Ulrich, Bryan C. AU - Guibert, Nicolas PY - 2018 TI - Non-invasive assessment of tumor PD-L1 status with circulating tumor cells JF - Annals of Translational Medicine; Vol 6, Supplement 1 (November 29, 2018): Annals of Translational Medicine Y2 - 2018 KW - N2 - Now FDA-approved in the treatment of over ten malignancies, checkpoint blockade agents have transformed the treatment of cancer. These agents work by inhibiting the PD-1/PD-L1 interaction between cytotoxic T cells and tumor cells, an interaction which promotes immune evasion. PD-L1 expression levels by tumor cells, as assessed by tissue biopsy, is currently the most well-validated and clinically used predictive biomarker of response to checkpoint blockade agents (1,2). However, PD-L1 level is known to be an imperfect biomarker, and some FDA approvals do not set a PD-L1 expression level threshold to determine patient candidacy for checkpoint blockade. UR - https://atm.amegroups.org/article/view/21814